Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Sep 21, 2020; 26(35): 5314-5327
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5314
Table 2 Analysis of immune escape-associated mutations in the major hydrophilic region in patients with and without resistance mutations
Clinical featuresResistance mutation (+), n = 6982Resistance mutation (-), n = 12458P valueThe MHR Mutation occurrence [(+) vs (-)]
Age in year44.01 ± 11.7339.01 ± 13.08< 0.05
Gender, male5709 (81.77%)9982 (80.13%)< 0.05
HBV genotype, C%/B%86.79/12.5283.00/16.05< 0.05
HBV DNA as log10 IU/mL4.62 (3.17, 6.47)4.24 (2.83, 6.16)< 0.05
sY100S20 (0.29%)29 (0.23%)NS
sQ101H/K/R298 (4.27%)229 (1.84%)< 0.05
sM103I/T8 (0.11%)14 (0.11%)NS
sL109I/P/R12 (0.17%)24 (0.19%)NS
sP111L/Q/S10 (0.14%)21 (0.17%)NS
sG112K/R4 (0.06%)9 (0.07%)NS
sS114A/L/T117 (1.68%)137 (1.10%)< 0.05
sT115A/N2 (0.03%)8 (0.06%)NS
sT116N6 (0.09%)32 (0.26%)< 0.05
sS117G/N/R5 (0.07%)19 (0.15%)NS
sT118A/K/M/R/S/V31 (0.44%)32 (0.26%)< 0.05
sG119E/R/T6 (0.09%)10 (0.08%)NS
sP120A/L/Q/S/T107 (1.53%)35 (0.28%)< 0.05
sC121R/S1 (0.01%)1 (0.01%)NS
sK122R154 (2.21%)315 (2.53%)NS
sT123A/I/N/S/V56 (0.80%)91 (0.73%)NS
sC124R/Y4 (0.06%)9 (0.07%)NS
sT125A/M8 (0.11%)21 (0.17%)NS
sT/I126A/N/P/S366 (5.24%)534 (4.29%)< 0.05
sP127H/L/S/T91 (1.30%)165 (1.32%)NS
sA128T/V7 (0.10%)15 (0.12%)NS
sQ129N/H/P/R90 (1.29%)129 (1.04%)NS
sG130A/K/N/R/S65 (0.93%)85 (0.68%)NS
sT131A/I/K/N133 (1.90%)219 (1.76%)NS
sS132F/P2 (0.03%)9 (0.07%)NS
sM133I/L/T196 (2.81%)277 (2.22%)< 0.05
sF/Y134H/L/R/S/V65 (0.93%)51 (0.41%)NS
sS136F/P/Y6 (0.09%)4 (0.03%)NS
sC137W/Y9 (0.13%)5 (0.04%)< 0.05
sC139R/S/Y3 (0.04%)9 (0.07%)NS
sT140I39 (0.56%)61 (0.49%)NS
sK141E/R3 (0.04%)4 (0.03%)NS
sP142L11 (0.16%)9 (0.07%)NS
sD144A/E17 (0.24%)26 (0.21%)NS
sG145A/R123 (1.76%)163 (1.31%)< 0.05
sC147R/Y00NS
sS154P1 (0.01%)2 (0.02%)NS
sA159G/V223 (3.19%)319 (2.56%)< 0.05
sV168A143 (2.05%)234 (1.88%)NS
Average number/patient0.350.27< 0.05
Patient percentage with the MHR mutation(s)23.32% (1628/ 6982)18.51% (2306/12458)< 0.05